Prophylactic Effect of Erythropoietin Injection to Prevent Acute Mountain Sickness: An Open-Label Randomized Controlled Trial
Journal of Korean Medical Science
;
: 416-422, 2014.
Article
in English
| WPRIM
| ID: wpr-112003
ABSTRACT
This study was performed to evaluate whether increasing hemoglobin before ascent by prophylactic erythropoietin injections prevents acute mountain sickness (AMS). This open-label, randomized, controlled trial involved 39 healthy volunteers with hemoglobin or =3 were present. Immediate descent criteria followed US Army recommendations. Two groups differ in hemoglobin levels on day 29 (15.4+/-1.1 vs 14.2+/-1.0 g/dL, P=0.001). At ABC, erythropoietin group had a significantly lower mean LLS, AMS incidence, and number of subjects who met immediate descent criteria. Multiple logistic regression analysis showed that SaO2<87% and control group, but not hemoglobin<15.0 g/dL, independently predicted satisfaction of immediate descent criteria. Erythropoietin-related adverse effects were not observed. In conclusion, erythropoietin may be an effective prophylaxis for AMS.(Clinical Trial Registry Number; NCT 01665781).
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oxygen
/
Blood Pressure
/
Recombinant Proteins
/
Hemoglobins
/
Drug Administration Schedule
/
Logistic Models
/
Odds Ratio
/
Acute Disease
/
Incidence
/
Surveys and Questionnaires
Type of study:
Controlled clinical trial
/
Etiology study
/
Practice guideline
/
Incidence study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS